<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056324</url>
  </required_header>
  <id_info>
    <org_study_id>Web-based vertigo rehab</org_study_id>
    <secondary_id>CIV-21-05-036744</secondary_id>
    <nct_id>NCT05056324</nct_id>
  </id_info>
  <brief_title>Web-based Rehab After Acute Vertigo</brief_title>
  <official_title>Internet-based Vestibular Rehabilitation Versus Standard Care After Acute Onset Vertigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sundsvall Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Västernorrland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Jämtland Härjedalen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Södra Älvsborg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunderby Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capio Sankt Görans Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute onset vertigo is common and entails much suffering with persisting symptoms at 3 months&#xD;
      after onset in up to half of those afflicted. Vestibular rehabilitation to aid recovery is&#xD;
      not readily available. The purpose of this study is to investigate the effects on vertigo&#xD;
      symptoms of a 6-week online vestibular rehabilitation tool compared with standard care&#xD;
      (written instructions leaflet) after acute onset vertigo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The between group mean Vertigo Symptom Scale Short Form (VSS-SF) score difference</measure>
    <time_frame>6 weeks after vertigo onset</time_frame>
    <description>VSS-SF uses a five-point Likert scale: 0 (never), 1 (a few times), 2 (several times), 3 (quite often [every week]), and 4 (very often [most days]). The score ranges from 0 to 60. A higher score indicates worse symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The between groups mean Dizziness Handicap Inventory (DHI) score</measure>
    <time_frame>6 weeks and 3 months after vertigo onset</time_frame>
    <description>The Dizziness Handicap Inventory (DHI) uses a three-point scale to rate each item: 0 (no), 2 (sometimes), and 4 (always). The score ranges from 0 to 100. A higher overall score indicates more severe handicap.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between groups changes in timed 25-foot walk test (T25-FW)); body sway during standing and walking; and the mobility</measure>
    <time_frame>From baseline to 6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between groups changes in video head impulse test (vHIT, site-dependent)</measure>
    <time_frame>6 weeks and 3 months after vertigo onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between groups changes in video head impulse test (vHIT, site-dependent) measured lateral canal VOR gain and saccades</measure>
    <time_frame>From baseline to 6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between groups mean vertigo symptom scale short form (VSS-SF) score</measure>
    <time_frame>12 months after vertigo onset</time_frame>
    <description>VSS-SF uses a five-point Likert scale: 0 (never), 1 (a few times), 2 (several times), 3 (quite often [every week]), and 4 (very often [most days]). The score ranges from 0 to 60. A higher score indicates worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between group pedometer-derived mean weekly number of steps walked since last visit</measure>
    <time_frame>3 months after vertigo onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between groups mean number of weekly training sessions</measure>
    <time_frame>6 weeks after vertigo onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Register-based search for health economic effects on all levels of care (primary, specialized) and society (sick leave)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in kinematic output between measurement systems (i.e., multi-sensor and mobile app)</measure>
    <time_frame>Three months after symptom onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reliability of the Swedish VSS-SF translation</measure>
    <time_frame>Six weeks after symptom onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of BPPV at 6 weeks and 3 months after AVS onset using a BPPV specific questionnaire and positional nystagmus tests</measure>
    <time_frame>6 weeks and 3 months after vertigo onset</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The proportion of participants who has experienced falls/fractures since study start</measure>
    <time_frame>6 weeks, 3 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of falls/fractures in each study arm</measure>
    <time_frame>6 weeks, 3 months and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Acute Vestibular Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Online vestibular rehabilitation tool</intervention_name>
    <description>For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care (written instructions leaflet)</intervention_name>
    <description>For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
          -  The subject has given written consent to participate in the study&#xD;
&#xD;
          -  New acute onset dizziness or vertigo since ≥24 hours with pathological spontaneous or&#xD;
             gaze-evoked nystagmus (i.e. an acute vestibular syndrome, AVS). The nystagmus as&#xD;
             described above must be present at screening (between 24 hours and 7 days from onset)&#xD;
             spontaneously, gaze-evoked or head-shake evoked and videofrenzel documented&#xD;
&#xD;
          -  Screening and inclusion within 7 days of onset of continuous symptoms&#xD;
&#xD;
          -  Symptomatic at inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing vestibular disease or neurological disease anticipated to affect the&#xD;
             ability to participate in the study or the effect of the intervention. N.B: Recurring&#xD;
             AVS with no set diagnosis before inclusion is accepted, as is past transient&#xD;
             neurological diseases such as TIA or migraine&#xD;
&#xD;
          -  Inability to use the online rehabilitation tool, e.g. due to not having access to a&#xD;
             computer, tablet or smartphone, not having access to the internet or lacking in&#xD;
             experience with such tools&#xD;
&#xD;
          -  Mental inability, reluctance or language difficulties that result in difficulty&#xD;
             understanding the meaning of study participation&#xD;
&#xD;
          -  Medical and/or physical contraindications to making the required head movements (e.g.&#xD;
             vertebral dissection) or otherwise participating in the training and testing exercises&#xD;
             or data collection&#xD;
&#xD;
          -  Medication or other substance intake which can affect the ability to participate in&#xD;
             the study or the reliability of the measurement methods. These medications include&#xD;
             regular use of: Anticonvulsants, antiemetics/motion sickness medications,&#xD;
             bensodiazepins, neuroleptics. Transient corticosteroid and/or antiemetic treatment&#xD;
             related to the current vertigo is accepted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonatan Salzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonatan Salzer, MD, PhD</last_name>
    <phone>+46 70 267 89 64</phone>
    <email>jonatan.salzer@umu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Södra Älvsborg Hospital</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ellen Lindell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hugo Davidsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Torbjörn Ledin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Skåne</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fredrik Tjernström, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sollefteå Hospital</name>
      <address>
        <city>Sollefteå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Bjurman, PT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio Sankt Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jan Mathé, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tatjana Tomanovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erik Faergemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunderby Hospital</name>
      <address>
        <city>Södra Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anette Sörlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonatan Salzer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Solmaz Surano, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Östersund Hospital</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erik Lundberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute vestibular syndrome</keyword>
  <keyword>vertigo</keyword>
  <keyword>vestibular rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Vestibular Diseases</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

